Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...

Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world ...

Bernice Kwong, MD, clinical professor of dermatology, Stanford University, expands on her session about graft-versus-host disease diagnosis and management presented at the 2022 American Academy of ...

GVHD is a major cause of morbidity and mortality following allogeneic hematopoietic cell transplantation. It is due to the donor T cells of a bone marrow or stem cell transplant attacking the host ...

There are now more drugs than ever to treat and prevent graft-versus-host disease in patients with blood cancer who receive a stem cell transplant. For many patients with blood cancers, an allogeneic ...

Patients undergoing matched-donor stem cell transplants lived four times longer without episodes of graft-versus-host disease (GVHD) with post-transplant cyclophosphamide-cyclosporin prophylaxis, a ...

Risk of graft-vs.-host disease, an often-debilitating and sometimes-deadly bone marrow transplant complication, can be reduced by matching key immune genes in a transplant recipient and their donor.

ROY ALWAYS ENJOYED life to the fullest. He thrived in his career as a graphic designer, while also making time for creative outlets like painting and playing the banjo. His favorite experiences, ...